http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014323344-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1621cf2e550c7620a6b69052aa7bcfbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e421a40bb6560bfd11074ed78df15353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c45a588f60f5206d2a0b11cadb95610b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07f287418853fb95bb4b0d1c2fc521cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a706926c5c3cb30b022a6c04d4365bda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff4a1917571aaea0053b2955f6229dc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a722b654284e5048e95706ffa2dd4ccb |
| publicationDate | 2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014323344-A1 |
| titleOfInvention | Differential Identification of Pancreatic Cysts |
| abstract | More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of DNA from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs) and solid pseudo-papillary neoplasms (SPNs). SPNs are low-grade malignancies, and IPMNs and MCNs, but not SCAs, have the capacity to progress to cancer. We found that SCAs, IPMNs, MCNs, and SPNs contained 10=4.6, 27=12, 16=7.6, and 2.9=2.1 somatic mutations per tumor, respectively. Among the mutations identified, E3 ubiquitin ligase components were of particular note. Four of the eight SCAs contained mutations of VHL, a key component of the VHL ubiquitin ligase complex that has previously been associated both with renal cell carcinomas, SCAs, and other neoplasms. Six of the eight IPMNs and three of the eight MCNs harbored mutations of RNF43, a gene coding for a protein with intrinsic E3 ubiquitin ligase activity that has not previously been found to be genetically altered in any human cancer. The preponderance of inactivating mutations in RNF43 unequivocally establish it as a suppressor of both IPMNs and MCNs. SPNs contained remarkably few genetic alterations, but always contained mutations of CTNNB1, previously demonstrated to inhibit degradation of the encoded protein (β-catenin) by E3 ubiquitin ligases. These results highlight the essential role of ubiquitin ligases in these neoplasms and have important implications for the diagnosis and treatment of patients with cystic tumors. |
| priorityDate | 2011-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 157.